Merck Discontinues Experimental Blood Cancer Drug Program
Merck said it would stop developing an experimental drug for certain blood cancers after a review suggested its benefits may not outweigh its risks.
Merck said it would stop developing an experimental drug for certain blood cancers after a review suggested its benefits may not outweigh its risks.